The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC

Lignende værker

• Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
  af: Baldacci, Simon, et al.
  Udgivet: (2017)
• Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
  af: Skrzypski, Marcin, et al.
  Udgivet: (2017)
• Management of acquired resistance to EGFR kinase inhibitors in advanced NSCLC
  af: Sacher, Adrian G., et al.
  Udgivet: (2014)
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
  af: Bria, E., et al.
  Udgivet: (2011)
• RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
  af: Nishino, Mizuki, et al.
  Udgivet: (2013)